Key Executives
| Name | Title | Pay | Exercised | Year Born |
|---|---|---|---|---|
| Mr. Ofer Gonen B.Sc. | Chief Executive Officer | 649k | -- | 1973 |
| Ms. Hani Luxenburg | Chief Financial Officer | 235k | -- | 1973 |
| Mr. Yaron Meyer Adv. | Executive VP, General Counsel & Corporate Secretary | 299k | -- | 1979 |
| Dr. Ety Klinger MBA, Ph.D. | Chief Research & Development Officer | 377k | -- | 1962 |
| Dr. Lior Rosenberg M.D. | Co-Founder | 727k | -- | 1946 |
| Dr. Shmulik Hess Ph.D. | COO & Chief Commercial Officer | -- | -- | 1973 |
| Dr. Liron Gal | Executive Director of Manufacturing Science & Technology | -- | -- | -- |
| Mr. Barry J. Wolfenson | Executive Vice President of Strategy & Corporate Development | -- | -- | 1967 |
| Dr. Robert J. Snyder CWS, D.P.M., F.A.C.F.A.S., FFPM, M.B.A., M.Sc. | Chief Medical Officer | -- | -- | 1950 |
MediWound Ltd.
- Sector:
- Healthcare
- Industry: Biotechnology
- Full Time Employees:
- 100
Description
MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.
Corporate Governance
Upcoming Events
March 19, 2025 at 12:30 PM UTC - March 24, 2025 at 12:30 PM UTC
MediWound Ltd. Earnings Date
Recent Events
September 5, 2024 at 12:00 AM UTC
CORRESP: A correspondence can be sent as a document with another submission type or can be sent as a separate submission